摘要
目的:探讨紫杉醇联合吉非替尼对食管癌患者的影响。方法:收治食管癌患者62例,采取随机数字表法分为观察组与对照组各31例,对照组给予单纯放疗治疗,观察组在对照组基础上给予紫杉醇联合吉非替尼化疗治疗。结果:观察组患者治疗总有效率和患者1、3、5年生存率,治疗满意率均高于对照组(P<0.05)。结论:紫杉醇联合吉非替尼化疗可提升食管癌患者治疗有效率,延长患者生存时间。
Objective:To investigate the effect of paclitaxel combined with gefitinib in patients with esophageal cancer.Methods:62patients with esophageal cancer were selected.They were randomly divided into the observation group and the control group with31cases in each.The control group were treated with radiotherapy,and the observation group were given paclitaxel combined with gefitinib chemotherapy,based on the treatment given in the control group.Results:The total effective rate,the survival rate at1,3,5years and treatment satisfaction rate in the observation group were higher than those in the control group(P<0.05).Conclusion:Paclitaxel combined with gefitinib chemotherapy can improve the treatment efficiency and prolong the survival time of patients with esophageal cancer.
作者
杨合军
Yang Hejun(Department of Thoracic Surgery,the People's Hospital of Linzhang County,Handan City of Hebei Province 056600)
出处
《中国社区医师》
2017年第14期84-85,共2页
Chinese Community Doctors
关键词
食管癌
紫杉醇
吉非替尼
生存率
不良反应
Esophageal cancer
Paclitaxel
Gefitinib
Survival rate
Adverse reaction
